Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021

Area of Science:

• Dermatology
• Clinical Practice Guidelines

Background:

• Atopic dermatitis (AD) is a relapsing eczematous disease with significant pruritus.
• Current Japanese guidelines focus on topical anti-inflammatories, barrier repair, and lifestyle management.
• The need for updated treatment strategies considering new therapeutic options is evident.

Purpose of the Study:

• To present an abridged English version of the 2021 Clinical Practice Guidelines for Atopic Dermatitis management.
• To incorporate recent advancements in AD treatment, including novel systemic and topical agents.
• To provide recommendations for evidence-based decision-making in clinical practice.

Main Methods:

• Review of clinical research articles on atopic dermatitis management.
• Evaluation of the advantages and disadvantages of various medical interventions.
• Synthesis of evidence to inform clinical practice recommendations.

Main Results:

• The guidelines detail three primary treatment measures: topical anti-inflammatories (corticosteroids, tacrolimus, delgocitinib), emollients for barrier dysfunction, and supportive care.
• New drug descriptions for dupilumab, delgocitinib, and baricitinib have been added.
• Recommendations focus on optimizing patient outcomes by balancing treatment efficacy and safety.

Conclusions:

• The revised guidelines offer a comprehensive, evidence-based approach to atopic dermatitis management.
• Integration of new therapies like dupilumab, delgocitinib, and baricitinib enhances treatment options.
• The guidelines aim to optimize clinical decision-making and improve patient outcomes in atopic dermatitis care.